10X Genomics (TXG) Stock Forecast & Price Target

10x Genomics is supported by a differentiated platform portfolio spanning Chromium, Chromium X, Visium, and Xenium, which positions it to serve multiple layers of biological research with integrated instruments, consumables, and software. The company’s broad geographic reach across the United States, Europe, China, and Asia-Pacific also diversifies demand, while its solutions address the need for higher-resolution, higher-scale analysis in complex biology, a durable tailwind for adoption. Together, these factors underpin a positive outlook because they support recurring consumables revenue, platform stickiness, and continued expansion across end markets.

10x Genomics is facing a negative outlook because its recent production results were below estimates and consensus, with gold, copper, and silver all missing expectations on lower planned grades and recoveries. Even with reiterated 2026 guidance of 420–470 koz AuEq, the weaker-than-expected operating performance suggests execution risk and limited near-term upside. The valuation still implies dependence on a 7.7x 2028E EV/revenue multiple, while the business remains unprofitable with 2028E revenue of $732.5M and EPS of -$0.40, even after factoring in $523M in cash, $84M in debt, and 130M shares outstanding.